Page last updated: 2024-11-06

2-hydroxypyrimidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Hydroxypyrimidine is a heterocyclic compound with a pyrimidine ring system. It is a tautomeric compound that exists in equilibrium between the 2-hydroxy and the 2-oxo forms. This compound is known for its ability to chelate metal ions, particularly zinc. Research on 2-hydroxypyrimidine focuses on its potential applications as a ligand in coordination chemistry, its role in biological systems, and its use as a precursor in the synthesis of other important compounds. Its importance stems from its ability to interact with various biological systems, particularly enzymes, as well as its potential applications in areas like drug discovery and material science. The compound is studied for its potential to inhibit the growth of bacteria and fungi, and its properties as a potential building block for new, more effective drugs.'

pyrimidone : A pyrimidine carrying one or more oxo substituents. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

pyrimidin-2-ol : The hydroxypyrimidine that is pyrimidine mono-substituted at C-2 by a hydroxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID68401
CHEMBL ID1650607
CHEBI ID53577
MeSH IDM0122644

Synonyms (52)

Synonym
AC-15597
557-01-7
2-hydroxypyrimidine
1,2-dihydropyrimidin-2-one
EN300-27696
nsc-618280
nsc618280
2-pyrimidinol
2(1h)-pyrimidinone
AB-323/25048086
pyrimidin-2-ol
51953-13-0
AKOS000117994
1h-pyrimidin-2-one
55949-38-7
CHEBI:53577 ,
2-pyridiminol
pyridiminol
CHEMBL1650607
2-oxopyrimidine
pyrimidin-2-one
unii-13k708ily4
einecs 209-149-8
13k708ily4 ,
A830762
pyrimidin-2(1h)-one
AM803987
AKOS016028433
pyrimidone
FT-0604349
DTXSID4060315
(1h)-pyrimidinone
1h-pyrimidinone
2-pyrimidone
2-pyrimidinol #
W-203100
2-oxopyrimidine(hcl salt form)
2-pyrimidinone
2(1h)-pyrimidone
GS-6298
mfcd00047358
2-pyrimidinol (7ci,9ci)
A871112
SY020185
FT-0751601
71o ,
Q17572764
2-pyrimidinol;
BCP30399
SB55522
O10847
CS-0021072
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Lewis baseA molecular entity able to provide a pair of electrons and thus capable of forming a covalent bond with an electron-pair acceptor (Lewis acid), thereby producing a Lewis adduct.
electron donorA molecular entity that can transfer an electron to another molecular entity.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
hydroxypyrimidine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566707Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (20.00)18.7374
1990's3 (30.00)18.2507
2000's4 (40.00)29.6817
2010's1 (10.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.95 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index52.86 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]